Is Butler promising patient groups the illusion of inclusion in HTA reforms?

In response to escalating frustration from patient organisations, Federal Health Minister Mark Butler met with more than 80 patient advocates amid growing uncertainty over whether patients will have any meaningful role in shaping the implementation of the Health Technology Assessment (HTA) Review reforms.

The tightly constrained 30-minute virtual meeting with patient organisations, facilitated by Patient Voice Initiative (PVI), took place on 9 July. It was intended to explore whether any genuine pathway exists to embed the patient voice into the negotiations underpinning the implementation of the HTA Review recommendations.

With no signal of funding in the May Federal Budget, the delivery of the HTA Review implementation has now been absorbed into the confidential Strategic Agreement negotiations between Medicines Australia and the Department of Health, which commenced this month.

The decision to incorporate HTA reform discussions into a closed-door negotiation process has intensified concerns among patient groups that the very stakeholders the reforms are designed to benefit will have limited visibility and influence over their delivery.

Health Industry Hub spoke with several patient advocacy groups following last week’s meeting with Minister Butler, with the overall takeaway described as “uninspiring”, “underwhelming” and “lacking substance”.

In his conversation with patient groups, Minister Butler acknowledged delays in implementing the HTA Review reforms, citing his focus on the National Disability Insurance Scheme (NDIS) reforms as a key contributing factor. He also agreed that the bundling of the HTA reforms process into the Strategic Agreement does indeed exclude patients.

However, Minister Butler maintained that the HTA Review process, since 2024, had involved patient groups and that the Department of Health is clear on what patients are seeking and expecting from the HTA Review implementation.

Yet the confidential nature of the Strategic Agreement remains the central tension. It restricts transparency, scrutiny and meaningful stakeholder engagement at precisely the point when patients argue their involvement is most critical. While patient organisations have participated in previous stages of the HTA Review process, they argue that consultation during a review does not automatically translate into influence during implementation.

Despite these concerns, Minister Butler has personally committed to attend a virtual meeting every 4-6 weeks with a small cohort of patient advocacy CEOs to provide updates on the progress of the HTA Review reforms and receive any further input that may be required along the way.

The commitment is ambitious and potentially difficult to sustain. For a Federal Health Minister managing one of the most demanding portfolios in government, personally attending meetings at such regular intervals raises questions over whether this represents a durable engagement model or an overcommitment that risks falling short of expectations.

The meeting with Minister Butler also became the only near-term opportunity for patient advocacy groups to seek access to the long-awaited HTA Review implementation roadmap, which remains withheld from public view despite being submitted to the Minister in December by the Implementation Advisory Group (IAG). The roadmap sets out clear timelines and costings mapped by the IAG for the implementation process. However, despite ongoing stakeholder interest, no further commitment has been provided regarding its public release.

Australia’s medicines debate has now entered a more intense political phase, with the battle over access increasingly spilling into public view.

Minister Butler has mounted a defence of the PBS as a system built on evidence and “good value for taxpayers”. However, critics argue that prolonged pricing negotiations and delayed PBS listings have created a structural barrier between Australians and life-extending treatments.

In a recent Health Industry Hub podcast, Liz de Somer, CEO of Medicines Australia, joined the conversation as pressure builds around delayed Pharmaceutical Benefits Scheme (PBS) listings, Most Favoured Nation (MFN) global pricing tensions and the direction of the HTA reforms.

The real challenge for Minister Butler is whether he can reconcile a promise of meaningful patient engagement with the risk of creating only the perception of inclusion while the substantive decisions on the HTA Review implementation remain firmly behind closed doors.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.